Assembly Biosciences Long-Term Investments 2010-2024 | ASMB
Assembly Biosciences long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
Assembly Biosciences Annual Long-Term Investments
(Millions of US $) |
| 2023 |
$ |
| 2022 |
$ |
| 2021 |
$28 |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$3 |
| 2016 |
$2 |
| 2015 |
$23 |
| 2014 |
$ |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Assembly Biosciences Quarterly Long-Term Investments
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
$12 |
| 2022-03-31 |
$23 |
| 2021-12-31 |
$28 |
| 2021-09-30 |
$9 |
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
$2 |
| 2018-03-31 |
|
| 2017-12-31 |
$3 |
| 2017-09-30 |
$1 |
| 2017-06-30 |
$3 |
| 2017-03-31 |
|
| 2016-12-31 |
$2 |
| 2016-09-30 |
$8 |
| 2016-06-30 |
$11 |
| 2016-03-31 |
$23 |
| 2015-12-31 |
$23 |
| 2015-09-30 |
$31 |
| 2015-06-30 |
$31 |
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.105B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
